Abbreviations
=============

AI

:   apoptotic index

AOM

:   azoxymethane

HAMS

:   high amylose maize starch

HAMSB

:   butyrylated high amylose maize starch

HAMSB0

:   base diet containing 0% HAMSB

HAMSB5

:   base diet containing 5% HAMSB

HAMSB10

:   base diet containing 10% HAMSB

HAMSB20

:   base diet containing 20% HAMSB

HAMSB40

:   base diet containing 40% HAMSB

RS

:   resistant starch

SCFA

:   short chain fatty acid

SSB

:   single-stranded DNA breaks

Introduction {#s0001}
============

Colorectal cancer (CRC) is one of the most common cancers world-wide and there is convincing evidence that consumption of dietary fiber is protective.[@cit0001] Dietary fiber consists largely of indigestible polysaccharides of plant origin which may be fermented by the colonic microbiota with the production of short chain fatty acids (SCFA), mainly acetate, propionate and butyrate. Of these acids, butyrate has an important role maintaining the homeostasis of the colonic mucosa and is a preferred energy source for colonocytes.[@cit0002] Its anti-tumorigenic potential has been investigated extensively, particularly its ability to enhance apoptosis in colorectal cancer cell lines in vitro,[@cit0003] and in the colonic epithelium of rats in response to acute exposure to genotoxin.[@cit0004] Butyrate has also been reported to promote differentiation[@cit0005] and to inhibit proliferation of colon cancer cells in vitro[@cit0006] at physiological concentrations by inhibiting histone deacetylase activity or other pathways involving G-protein coupled receptors.[@cit0007]

Acylated starches have been shown to be an effective means of delivering specific SCFA to the large bowel of humans[@cit0008] and animals[@cit0010] and butyrylated high amylose maize starch (HAMSB) has been shown to protect the colonic mucosa of rats from DNA damage induced by high dietary protein[@cit0011] and reduce both incidence and number of colonic tumors in the azoxymethane (AOM)-induced rat model of CRC.[@cit0012] Although butyrate plays a major role regulating apoptosis, differentiation and proliferation in the colonic epithelium,[@cit0013] some in vitro studies have demonstrated that CRC cells can escape from butyrate-induced apoptosis and become butyrate-resistant.[@cit0014] Human CRC cells, selected in vitro for this ability to grow in the presence of butyrate, produce tumors with more aggressive phenotypes than did unselected cells from the parental CRC cell line when introduced either subcutaneously or orthotopically into a mouse xenograft cancer model.[@cit0016] However, it remains unclear whether prolonged exposure to elevated concentrations of butyrate selects for resistance to butyrate-induced apoptotic deletion of cells in the colonic mucosa that have undergone acute DNA damage. It has also been suggested that enhanced large bowel fermentation can promote intestinal tumor formation in Apc^min/+^ mice.[@cit0017]

The aim of this study was to investigate the dose effects of butyrate delivered by dietary HAMSB on the acute apoptotic and proliferative responses of the distal colonic epithelium to genotoxic challenge with AOM. We have examined the effects of diets containing 0--40% HAMSB on the mucosal responses in relation to the level of colonic epithelial DNA damage as assessed by the COMET assay. In addition, changes to other biomarkers relevant to CRC risk were also examined.

Results {#s0002}
=======

Animal and digesta measures {#s0002-0001}
---------------------------

Final body weights and food intakes were unaffected by the dietary treatment ([**Table 2**](#t0002){ref-type="table"}). Daily water intake increased with level of HAMSB ingestion with HAMSB20 and HAMSB40 rats drinking significantly more than HAMSB0 rats (*P* \< 0.01). Table 1.Composition of experimental diets^a^ Experimental diets (g/kg) IngredientHAMSB0 g/kg dietHAMSB5HAMSB10HAMSB20HAMSB40Casein^b^200200200200200Low amylose maize (LAMS) starch**^c^**530480430330130Butyrylated HAMS (HAMSB)**^d^**050100200400Sucrose100100100100100Sunflower oil7070707070α-cellulose5050505050[L]{.smallcaps}-Cystine33333Choline bitartrate2.52.52.52.52.5Vitamins (AIN 93-G)**^e^**1010101010Minerals (AIN 93-G)**^e^**3535353535[^1][^2][^3][^4][^5] Table 2.Final measures of rats fed diets for 28 d containing HAMS and HAMSB and killed 6 hours after injection with AOM Dietary treatment HAMSB0HAMSB5HAMSB10HAMSB20HAMSB40Final weight (g)406 ± 12400 ± 5405 ± 9392 ± 9372 ± 10Daily food intake (g/day)18.3 ± 1.119.3 ± 0.418.7 ± 0.520.0 ± 0.621.4 ± 0.9Daily water intake (ml/day)17.8 ± 1.0^a^22.1 ± 0.8^ab^23.8 ± 1.8^ab^27.3 ± 2.0^b^28.3 ± 2.8^c^Cecal measurements      pH7.02 ± 0.05^a^6.72 ± 0.13^ab^6.41 ± 0.07^bc^6.11 ± 0.09^c^5.75 ± 0.03^d^ Digesta weight (g)1.9 ± 0.2^a^2.9 ± 0.2^a^3.2 ± 0.3^a^7.3 ± 0.3^b^19.7 ± 1.8^c^ Tissue weight (g)0.58 ± 0.02^a^0.74 ± 0.03^a^0.92 ± 0.04^a^1.39 ± 0.11^b^2.65 ± 0.15^c^ Moisture (%)75.8 ± 0.7^a^80.3 ± 1.1^bc^79.8 ± 0.7^b^83.5 ± 0.8^bc^89.0 ± 0.6^d^ \^Ammonia pool (nmoles)172 ± 17^a^106.7 ± 21.7^ab^69.5 ± 8.9^bc^48.6 ± 6.8^bc^45.2 ± 5.6^c^Colon measurements      Length (cm)18.8 ± 0.3^a^19.2 ± 0.4^a^19.6 ± 0.4^a^21.2 ± 0.3^b^23.5 ± 0.3^c^ Distal colon pH6.53 ± 0.04^a^6.18 ± 0.05^b^5.98 ± 0.04^bc^5.83 ± 0.08^c^5.82 ± 0.08^c^ Mucus layer thickness (μm) 167 ± 10^a^191 ± 9^ab^202 ± 13^ab^218 ± 10^b^224 ± 5^b^ \^Ammonia pool (nmoles)25.3 ± 3.8^a^20.8 ± 7.1^ab^11.56 ± 2.1^ab^8.0 ± 3.2^b^8.5 ± 3.2^b^Small intestine measurements      Length (cm)128 ± 2^a^128 ± 2^a^130 ± 2^a^134 ± 2^a^147 ± 2^b^ pH7.74 ± 0.11^a^7.71 ± 0.06^a^7.61 ± 0.08^a^7.61 ± 0.09^a^6.85 ± 0.08^b^Faecal measurements      pH6.40 ± 0.05^a^6.12 ± 0.06^ab^6.19 ± 0.17^b^5.71 ± 0.08^c^5.97 ± 0.11^bc^ Output (g/day)2.3 ± 0.2^a^3.1 ± 0.1^a^5.1 ± 0.2^b^7.1 ± 0.2^c^11.0 ± 0.5^d^ \^Moisture (%)39 ± 3^a^57 ± 7^ab^66 ± 2^abc^73 ± 1^bc^87 ± 2^c^Urine output (ml/day)6.8 ± 0.59.3 ± 0.89.1 ± 1.812.4 ± 2.210.1 ± 2.6[^6][^7]

Cecal digesta weight was increased proportionally with dietary HAMSB content and was increased substantially in the HAMSB40 group. This was accompanied by greater cecal tissue weight and lower cecal digesta pH ([**Table 2**](#t0002){ref-type="table"}).

Colonic length increased dose dependently with the level of HAMSB intake and was greater in rats fed HAMSB40 than in those fed HAMSB20. The colons of rats in both of these groups were significantly longer than those in the HAMSB0, HAMSB5 and HAMSB10-fed rats. Distal colonic digesta and faecal pH decreased with dietary HAMSB intake. The small intestine was longer and digesta pH lower for HAMSB40-fed rats compared to all other diets (*P* \< 0.05) ([**Table 2**](#t0002){ref-type="table"}).

Faecal output was higher in proportion to the HAMSB content of the diet ([**Table 2**](#t0002){ref-type="table"}) with the output of the HAMSB20 and HAMSB40 rats being significantly higher than all other groups. There were no significant differences in urinary output between dietary groups. The cecal digesta and faecal moisture contents increased with dietary HAMSB intake ([**Table 2**](#t0002){ref-type="table"}) with HAMSB40 ingestion resulting in faecal moisture levels higher than any other group and over double the HAMSB0 group. The HAMSB40 diet resulted in intermittent diarrhea in several rats, which was reflected in their greater water intake and faecal moisture content.

Colonic mucus layer thickness {#s0002-0002}
-----------------------------

The colonic mucus layer became thicker with increased dietary HAMSB intake ([**Table 2**](#t0002){ref-type="table"}). Correlation analysis showed that cecal butyrate pools were related positively to colonic mucus thickness ([**Table 3**](#t0003){ref-type="table"}; r = 0.48, *P* \< 0.0001). Table 3.Correlations between selected indices and faecal and colonic parameters AISSBMucus thickness r*P* valuer*P* valuer*P* valueHepatic portal plasma       Acetate concentration0.49\<0.0001−0.480.003NSNS Butyrate concentration0.65\<0.0001−0.64\<0.00010.350.002Cecal SCFA pools       Acetate pool0.48\<0.0001−0.450.0050.390.0007 Butyrate pool0.60\<0.0001−0.660.00010.48\<0.0001 Cecal ammonia pool−0.56\<0.00010.540.0009−0.390.0007 Mucus thickness0.400.0005−0.350.04------ SSB−0.450.0055    [^8]

Hepatic portal vein plasma, cecal and faecal SCFA concentrations and pools {#s0002-0003}
--------------------------------------------------------------------------

Hepatic portal plasma total SCFA, acetate and butyrate concentrations increased with higher intakes of dietary HAMSB ([**Fig. 1A**](#f0001){ref-type="fig"}). However, there was no difference in hepatic portal vein plasma propionate concentrations. Figure 1.Short chain fatty acid levels in (**A**) hepatic portal vein plasma concentrations (μmol/L) (**B**) cecal pools (μmoles) (**C**) cecal concentrations (μmol/L) (**D**) faecal pools (μmoles). Columns within a graph not sharing the same letter are significantly different *P*\< 0.05, mean±SEM , n = 15/group).

Cecal total SCFA, acetate and propionate concentrations decreased with increasing level of dietary HAMSB intake ([**Fig. 1B**](#f0001){ref-type="fig"}). The rats fed HAMSB5--20 had higher cecal butyrate concentrations than HAMSB0-fed rats but were lower with high intakes of dietary HAMSB due to expansion of the digesta mass.

HAMSB10--20 fed rats had higher faecal acetate and total SCFA pools compared to HAMSB0 fed rats, and HAMSB5-20 groups had higher faecal butyrate pools than HAMSB0 rats. The butyrate and total SCFA pools of the HAMSB40 rats were higher than any other group ([**Fig. 1D**](#f0001){ref-type="fig"}). There were no differences in faecal propionate pools.

Hepatic portal plasma butyrate concentrations were positively correlated with cecal butyrate pools but not concentrations (r = 0.79, *P* \< 0.0001; r = 0.21, *P* = 0.07 respectively).

Distal colonic apoptosis and proliferation indices {#s0002-0004}
--------------------------------------------------

Distal colonic AI increased with level of dietary HAMSB inclusion ([**Fig. 2A**](#f0002){ref-type="fig"}). The AI of the HAMSB40 fed rats was over twice that in the HAMSB0-fed rats (*P* \< 0.001) and correlated positively with hepatic portal acetate and butyrate concentration (r = 0.49, *P* \< 0.0001 and r = 0.65, *P* \< 0.0001 respectively) but not propionate. Figure 2.Analysis of the distal colon of rats fed HAMSB and killed 6 hours after AOM injection. (**A**) AI as measured by morphological assessment of haematoxylin stained slides (n = 15/group) (**B**) Epithelial proliferation as measured by Ki67 immunohistochemistry (n = 15/group) (**C**) Genetic damage as measured by single-cell gel electrophoresis (comet) assay (n = 10/group). Columns within a graph not sharing the same letter are significantly different (*P* \< 0.05, mean±SEM ).

HAMSB increased the rate of apoptosis in a dose-related manner in cells in the distal colon in cellular positions 1 to 20, with the effect being most marked from the base of the crypt (position 1) to around position 15 ([**Fig. 3**](#f0003){ref-type="fig"}). Figure 3.Crypt cell position of AOM-induced apoptosis measured by morphological assessment of distal colonic epithelium in distal colon of rats fed HAMSB. Data are mean±SEM (n = 15). ^a,b,c^HAMSB0 different to HAMSB10, HAMSB20 and HAMSB40 respectively (*P*\<0 .05).

The rate of colonic epithelial proliferation was not influenced by dietary treatment ([**Fig. 2B**](#f0002){ref-type="fig"}).

Colonocyte DNA damage {#s0002-0005}
---------------------

DNA damage (measured as SSB) was greatest when the diet did not contain HAMSB and decreased as the HAMSB content increased ([**Fig. 2C**](#f0002){ref-type="fig"}). Colonic DNA damage correlated negatively with hepatic portal butyrate concentration (r = −0.64, *P* \<0 .0001) and cecal butyrate pool (r = −0.66, P = 0.0001) ([**Table 3**](#t0003){ref-type="table"}).

Large bowel ammonia {#s0002-0006}
-------------------

Cecal ammonia pools were lower in rats fed HAMSB5, and lower still in rats fed HAMSB40 than HAMSB0-fed rats, whereas distal colonic ammonia pools were lower in rats fed HAMSB20 and HAMSB40 than HAMSB0 rats ([**Table 2**](#t0002){ref-type="table"}). Correlation analysis suggested a negative association between AI and cecal ammonia pool (r = −0.56, *P* \< 0 .0001) and a positive association between level of DNA damage and cecal ammonia pool (r = 0.54, *P* = 0.009) ([**Table 3**](#t0003){ref-type="table"}).

Discussion {#s0003}
==========

This study demonstrates for the first time that elevation of butyrate levels in the large bowel of rodents by increasing dietary HAMSB dose-dependently lowers colonic epithelial DNA damage and increases rates of apoptotic deletion of carcinogen-challenged cells in the distal colon in rats. Importantly these dose-dependent effects are not associated with an increase in cellular proliferation. The relationships between cecal digesta butyrate pools and hepatic portal butyrate concentrations support our previous studies in which elevated large bowel butyrate enhanced apoptosis[@cit0004] and reduced tumor incidence and number[@cit0012] in AOM-treated rats and lowered colonic DNA damage induced by a high protein diet.[@cit0011] DNA damage is linked closely to risk of carcinogenesis[@cit0018] so increasing the rate of apoptosis of damaged cells is likely to be an important contender for the CRC-protective effect of dietary HAMSB and other factors which increase large bowel butyrate. This present study suggests that at least one mechanism by which butyrate protects against colon carcinogenesis may involve increasing the stringency of apoptotic surveillance by reducing the threshold of DNA damage needed to induce apoptosis in colonocytes.

Butyrate induces apoptosis in cancer cells through various mechanisms[@cit0007] including alteration of gene transcription via histone deacetylase (HDAC) activity[@cit0020] and parallel activation of mitochondrial-dependent intrinsic and receptor mediated extrinsic pathways.[@cit0021] Through inhibition of HDAC and alteration of chromatin, butyrate induces expression of target genes that regulate proteins involved in apoptosis as well as cell cycle regulation and DNA repair.[@cit0006] Butyrate has also been shown to induce apoptosis via activation of G protein coupled receptor 43 (GPR43) which is frequently lost in colon cancer cells.[@cit0023] The genes encoding the various receptors and transporters involved in butyrate-induced apoptosis are often silenced in CRC cell lines.[@cit0024] For example the butyrate transporter SLC5A8 (SMCT1) gene is commonly silenced epigenetically by aberrant methylation early in human colonic neoplasia[@cit0025], but facilitates butyrate-induced cellular apoptosis when re-expressed in the presence of butyrate.[@cit0026] Together these data suggest that the evasion of butyrate-induced apoptosis may be a key step in colorectal oncogenesis. Situations of extensive DNA damage and compromised repair may result in the accumulation of mutations or silencing of repair and apoptotic genes. Hence a facilitator like butyrate that enhances the deletion of genetically damaged cells would play a key role in maintaining a healthy colonic mucosa.

In the colon, stem cells proliferate at the base of the crypt producing both pluripotent stem cells and daughter cells which differentiate into mature goblet and absorptive cell types as they move from the bottom of the crypt to the lumen (for reviews, see Refs.[@cit0027]). The present demonstration that elevated large bowel digesta butyrate levels can dose-dependently promote apoptosis in the base and mid sections of the colonic crypts suggests that deletion of damaged stem and daughter cells may represent a key mechanism by which dietary butyrylated starch brought about a reduced incidence and number of colonic tumors in AOM treated rats.[@cit0012] Further, this may go some way to explaining how high daily intakes of dietary fiber, particularly fermentable carbohydrates like resistant starch, can reduce the risk of CRC.[@cit0001]

In the current study, elevation of large bowel butyrate levels did not increase the rates of colonocyte proliferation over those observed within the colonic crypts of controls. This contrasts with observations in Apc^min/+^mice where the feeding of fermentable fiber increased polyp size and, in morphologically normal regions of the colon, elevated epithelial cell proliferation and crypt fission.[@cit0017] Coupled with the discovery that human CRC cell lines selected for resistance to the apoptotic effects of butyrate displayed more aggressive tumor phenotypes in a mouse xenograft cancer model[@cit0015] than their parental lines, this raised the possibility that prolonged elevation of butyrate levels in the large bowel may lead to loss of sensitivity to butyrate-induced apoptosis by the colonic epithelium when damaged acutely by genotoxins, resulting in greater risk of more numerous and aggressive tumors. However more recent studies have shown physiological concentrations of butyrate have been found to inhibit proliferation of apoptosis-resistant CRC cells, possibly by the activation of the MAPK signaling pathway.[@cit0006] In addition our previous study investigating the impact of dietary HAMSB on colorectal tumor formation using the AOM rat model showed a reduction of large bowel tumor number and incidence with no impact on tumor size when compared with LAMS-fed control animals.[@cit0012] Overall we concluded that, at least in situations when butyrate is delivered by acylated starch, the net effect of prolonged exposure to increased large bowel butyrate supply is greater protection against tumor formation.

Acylated starches were designed as a vehicle for the rapid and sustained delivery of butyrate to the colon.[@cit0010] Acylated HAMS is twice as effective in raising the concentration of the esterified SCFA as the parent starch.[@cit0030] The present study shows that although cecal butyrate pools increase dose-dependently with HAMSB consumption, cecal butyrate concentrations are lowered at high levels of HAMSB intake due to increased digesta bulk and moisture levels from cecal fermentation of the additional resistant starch. Nevertheless, at high levels of HAMSB intake SCFA concentrations in the hepatic portal vein plasma were closely correlated with cecal SCFA pools rather than concentrations suggesting the former are more accurate indicators of the amount of esterified SCFA in the large bowel available to the host tissues. This observation reflects the fact that butyrate uptake into colonocytes is driven by active mucosal transport mechanisms as well as passive diffusion along a concentration gradient so the butyrate pool is more critical than its concentration.

The genotoxicity of AOM could be affected by differences in digesta mass between the groups. Only a proportion of injected AOM is delivered via the digesta with the remainder being distributed to tissues via the circulatory system.[@cit0031] However, the relationship between cecal digesta weight and DNA damage appeared to plateau at relatively moderate cecal digesta weights with higher rates of accretion not affecting the level of DNA damage. Dietary sources of nonstarch polysaccharides (such as wheat bran) are most effective at increasing digesta faecal bulk, largely due to the passage of unfermented material, whereas resistant starch (including HAMSB) is generally of high fermentability and has a limited effect.[@cit0032] Protection from developing CRC is more closely associated with intake of fermentable rather than indigestible carbohydrates.[@cit0033]

Ammonia is a recognized cytotoxic and carcinogenic agent.[@cit0034] Ammonia is in pH dependent equilibrium with its protonated ammonium ion form and ammonia, but not the ammonium ion, is able to passively diffuse into the cells of the colonic mucosa[@cit0036] and thence on into the circulation, for ultimate excretion via the kidneys. The lowering of the digesta pH resulting from release of butyrate from HAMSB and the fermentation of the resistant carrier starch favors ammonium ion formation, a faecal path for ammonia excretion and hence increased protection of the colonocytes from the toxic effects of this agent.

Increasing dietary HAMSB content was associated with a dose dependent increase in mucus layer thickness in the distal colon of the rats. The colonic mucosa provides a critical barrier to the entry of bacteria and toxins from the lumen into the tissues of the colon and the systemic circulation. The thickness of the mucus layer provides one important measure of gut barrier function.[@cit0037] The outer, non-adherent, mucus layer is thought to act by reducing shear stress to the mucosa while the inner mucus layer acts as a size exclusion barrier to potentially damaging luminal agents. Our observations here confirm several previous studies demonstrating that butyrate increases the mucin layer covering the colonic epithelium[@cit0038] more effectively than other SCFA.[@cit0039] Our results are also consistent with in vitro studies that have shown butyrate to increase expression of the mucin-encoding gene, Muc2 in cultured cells.[@cit0040] Reduction of MUC2 expression is frequently seen in ulcerative colitis patients[@cit0042] and other inflammatory bowel diseases where loss of barrier function is a prominent clinical feature.[@cit0043] Increased risk of CRC in IBD patients may relate in part to the compromised mucus layer allowing carcinogenic compounds greater access to the colonic mucosal cells. Hence it is likely that another part of the protective effect of HAMSB with respect to DNA damage in the current study and reduction in CRC burden in the long term AOM rat model may result from the enhanced mucus layer.

In conclusion, we have demonstrated that dietary HAMSB provides a dose-related reduction in the level of DNA damage and an increase in the rate of apoptotic deletion of damaged colonic epithelial cells after acute treatment with AOM. Rates of colonic epithelial proliferation were unaffected even at high intakes of HAMSB. Early removal of damaged cells may account, at least in part, for butyrate\'s observed ability to reduce the risk of AOM-induced CRC in rats. However it remains to be determined whether elevating butyrate concentration in the colon of humans has similar protective effects.

Materials and Methods {#s0004}
=====================

Animals and diets {#s0004-0001}
-----------------

Seventy-five 4 week old male Sprague Dawley rats were purchased from the Animal Resource Center, Murdoch University, Perth, Western Australia. After acclimatisation for one week in the CSIRO animal facility rats were allocated to one of 5 groups (n = 15/group) so that mean body weights were similar across those groups (180 ± 2 g; mean ± SEM). The rats were housed in wire-based cages to minimise coprophagy in rooms maintained at 23 ± 1ºC with a 12 h light/dark cycle. They were given free access to food and water and were weighed weekly throughout the study.

Each group of animals was fed one of 5 diets ([**Table 1**](#t0001){ref-type="table"}). The diets were based on a balanced modification of the AIN-93G diet[@cit0044] containing α-cellulose as the (non-fermentable) fiber source. The amount of low amylose maize starch (Avon Maize Starch, New Zealand Starch Ltd, Auckland, New Zealand) in the diet was reduced to allow for the addition of 5, 10, 20, 40 % HAMSB. HAMSB was prepared for CSIRO by Ingredion Inc. (Bridgewater, New Jersey) and had a degree of substitution (DS) of 0.23 \[i.e. 0.23 of the hydroxyl groups on each starch D-glucopyranosyl unit were derivatized or replaced by the substituent acid[@cit0045]\]. The diets were mixed, pelleted, and dried overnight at 45ºC and stored frozen at -20ºC until fed to the rats.

After 14 d of feeding the experimental diets rats (n = 8 per group) were placed in metabolic cages for 3 d to enable the accurate determination of food and water intakes and faecal and urinary outputs. After 28 days of being fed the experimental diets each rat was injected with 15 mg AOM/kg subcutaneously (Sigma Chemical Co., St Louis, MO). Six hours later the rats were anaesthetised with isoflorane (Isoflo, Abbott Animal Health, Abbott Park, IL) and blood collected from the hepatic portal vein and abdominal aorta. The length of the colon was recorded, 0.5 cm discarded from proximal and distal ends, and 1cm sections collected from both distal and proximal ends of the remaining colon. The tissues were fixed in 10% buffered formalin for 24 h, processed and then embedded in paraffin. Cross sections of 4 μm thickness were cut for all histological techniques. The cecum was removed, weighed and known weights of cecal and colonic digesta collected and homogenized in 3 × weight volume of SCFA internal standard solution (1.68 mM heptanoic acid diluted in Milli-Q water adjusted to pH 7) and vortexed for 30 seconds. The pH was measured and then the samples were frozen and stored at −20° C for SCFA analysis. Hepatic portal vein blood was collected into Vacuette tubes containing lithium heparin (Greiner Bio-One, Kremsmuenster, Austria) for plasma analyses. All blood samples were centrifuged at 2000 × g for 15 minutes and aliquots stored at −80°C until analyzed.

All procedures involving animals were approved by the Commonwealth Scientific and Industrial Research Organization (CSIRO) Animal, Food and Health Sciences Animal Ethics Committee and complied with the NHMRC Australian code of practice for the care and use of animals for scientific purposes 7^th^ edition.[@cit0046]

Colonic apoptosis/ haematoxylin {#s0004-0002}
-------------------------------

Samples of distal colonic tissue were processed and morphologically assessed for rates of epithelial apoptosis as described previously.[@cit0004] Briefly, sections (4 μm) were stained with haematoxylin (BDH Laboratory Supplies, UK) and evaluated under a light microscope (BX41, Olympus, Tokyo, Japan) for apoptotic cells. These cells were identified in 20 randomly chosen intact crypts by cell shrinkage, presence of condensed chromatin, and sharply delineated cell borders surrounded by a clear halo as described by Potten et al.[@cit0047] The apoptotic index (AI) was calculated as the mean number of apoptotic cells divided by the total number of cells in the crypt column multiplied by 100 (represented as percentage). The crypt height and position of apoptotic cells were also recorded. All slides used for assessment of rates of apoptosis and proliferation were encoded randomly and examined by an independent observer who was unaware of the dietary treatments.

Colonic cell proliferation {#s0004-0003}
--------------------------

The rates of distal colonic epithelial proliferation were measured using a modified version of a Ki67 immunohistochemistry method as described previously.[@cit0004] The present study decreased the dilution of monoclonal antibody (Ki67, DAKO, Glostrup, Denmark) from 1/200 to 1/100 to increase the visibility of stain.

Colonic genotoxicity/Comet assay {#s0004-0004}
--------------------------------

A 6-cm segment of colon was removed from each rat at a point 3cm from the distal end of the colon and placed in a solution containing HBSS with 20mM EDTA and 10% DMSO and transferred to −80°C for storage. At the time of analysis the tissue was thawed, the colonic mucosa removed from the luminal surface of the tissue (ie epithelial cells collected by scraping mucosa with a glass microscope slide using even pressure) and the scrapings thoroughly dispersed for 2 minutes using a hand-held homogenizer (Wheaton scientific, Millville NJ, 0.1--0.15 mm gauge). Cells were then passed into a TV-10 tube through a 25 μm nylon filter (Millipore, Billerica, MA) held in a Swinnex filter (Millipore, Billerica, MA) to remove large aggregates of unseparated cells. A single cell suspension was then prepared as described by Thomas.[@cit0048] These cells were used for the measurement of DNA single-strand breaks (SSB) using the single-cell gel electrophoresis (COMET) assay as described previously using the COMET Assay Kit (Trevigen, Gaithersburg, MD).[@cit0049] COMET tail moment is the product of tail length and the fraction of DNA in that tail and was calculated for 50 cells from each of 3 slides per rat. The measure was calculated by CometScore Freeware v1.5 (TriTek Corporation, Summerduck, VA) analysis software.

Sampling and analysis procedures {#s0004-0005}
--------------------------------

SCFA concentration in faeces and cecal digesta and total ammonia nitrogen concentration in cecal and distal colonic digesta were determined as described previously.[@cit0030] The concentration of digesta ammonia (NH~3~) was calculated using the Henderson-Hasselbalch equation and the pKa of ammonia of 9.25. The digesta weights and ammonia concentrations were used to calculate the cecal and distal colonic ammonia pools. The samples were also freeze-dried to determine moisture content.

Colonic mucus layer thickness {#s0004-0006}
-----------------------------

A 1-cm segment of colon was collected at 2--3 cm from the distal end of the colon of each rat. The segment was cut open along the anti-mesenteric ridge and the mucosal surface washed gently with 0.15 M NaCl solution to remove digesta. The thickness of mucus lining the distal colon was determined by cutting the tissue into 1.6 mm lengths, illuminating and capturing images of the mucus layer to measure the thickness using an image analysis program.[@cit0050] For each animal 10 measurements were taken at different points along 4 tissue segments to give 40 thickness measurements in total.

Statistical analysis {#s0004-0007}
--------------------

All analyses were performed using GraphPad Prism Version 6.00 (GraphPad Software Inc.. San Diego, CA) and all data are expressed as mean ± standard error of the mean (SEM). One-way analysis of variance (ANOVA) with Tukey post-hoc tests (parametric data) and Kruskal-Wallis tests with Dunn\'s post-hoc test (non-parametric data) were used to compare data between treatment groups. The mean apoptotic cell count at crypt cell positions 1--17 in the distal colon of rats fed HAMSB were compared to LAMS counts using ANOVA with Dunnett\'s multiple comparison tests for parametric data. For cell positions 18--20 Kruskal-Wallis with Dunn\'s multiple comparison tests were used to compare the mean rank of each column with the mean rank of LAMS. The correlations between variables were undertaken using the Spearman\'s nonparametric correlation test for analyses involving AI, hepatic portal plasma and cecal SCFA pool and cecal ammonia pool as these data were non-parametrically distributed. Pearson\'s correlation tests were used for SSB and mucus thickness as these parameters were normally distributed. Differences were considered significant when *P* \< 0.05.
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[^1]: Based on the AIN93-G diet ^44^

[^2]: Casein supplied by Murray Goulburn Co-Operative (Southbank, Victoria Australia)

[^3]: Low amylose maize starch (Avon Maize Starch) supplied by New Zealand Starch Ltd (Auckland, New Zealand)

[^4]: HAMSB manufactured by Ingredion Inc. (New Jersey, USA)

[^5]: AIN93-G vitamin and mineral mixes supplied by MP Biomedicals (Seven Hills, NSW Australia)

[^6]: Values are the mean±SEM (n = 15). \^Nonparametric Kruskal-Wallis test used.

[^7]: Mean values with a different superscript within each row are significantly different (**P** \< 0.05)

[^8]: Spearman\'s correlation was used for all parameters except mucus thickness and SSB. Both these measures were normally distributed and Pearson\'s correlations were used.
